KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Common Equity (2016 - 2025)

Historic Common Equity for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $85.1 million.

  • Nektar Therapeutics' Common Equity rose 7405.7% to $85.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.1 million, marking a year-over-year increase of 7405.7%. This contributed to the annual value of $60.7 million for FY2024, which is 5363.13% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Common Equity of $85.1 million as of Q3 2025, which was up 7405.7% from -$24.2 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Common Equity high stood at $994.5 million for Q1 2021, and its period low was -$24.2 million during Q2 2025.
  • For the 5-year period, Nektar Therapeutics' Common Equity averaged around $333.9 million, with its median value being $197.0 million (2023).
  • Examining YoY changes over the last 5 years, Nektar Therapeutics' Common Equity showed a top increase of 7405.7% in 2025 and a maximum decrease of 13038.22% in 2025.
  • Over the past 5 years, Nektar Therapeutics' Common Equity (Quarter) stood at $679.5 million in 2021, then crashed by 46.04% to $366.6 million in 2022, then crashed by 64.27% to $131.0 million in 2023, then tumbled by 53.63% to $60.7 million in 2024, then soared by 40.09% to $85.1 million in 2025.
  • Its Common Equity stands at $85.1 million for Q3 2025, versus -$24.2 million for Q2 2025 and $13.7 million for Q1 2025.